Auto saved by Logseq

pages/STOP2030___Web___Posts.md

@@ -18,20 +18,11 @@
 	- # The REALISE clinical trial is registered
 	  
 	  At STOP2030, we aim to provide a pharmacological tool that aids in achieving the WHO's goals for
-	  soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on [clinicaltrials.gov](https://urldefense.com/v3/__https:/clinicaltrials.gov/study/NCT06282315__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncW8CTAdM$) and
-	  the [Pan African Clinical Trial
-	  Registry](https://urldefense.com/v3/__https:/pactr.samrc.ac.za/Search.aspx__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncACmxOT0$) (id number PACTR202402529220760). This news follows the
-	  approval from the Ghana Health Service Ethical Review Committee, obtained in
-	  December, 2023.
+	  soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on [clinicaltrials.gov](https:/clinicaltrials.gov/study/NCT06282315__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncW8CTAdM$) and the [Pan African Clinical Trial
+	  Registry](https:/pactr.samrc.ac.za/Search.aspx__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncACmxOT0$) (id number PACTR202402529220760).
 	  
-	  
-	  
-	  This randomized control trial is a
-	  Cohort Event Monitoring study designed to evaluate the safety and effectiveness
-	  of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large
-	  populations, compared to the standard dose of albendazole currently used
-	  against STH. We plan to recruit around 20,000 school-aged children between 5
-	  and 17 years old in Kenya and Ghana, starting in July 2024.
+	  This randomized control trial is a Cohort Event Monitoring study designed to evaluate the safety and effectiveness of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large
+	  populations, compared to the standard dose of albendazole currently used against STH. We plan to recruit around 20,000 school-aged children between 5 and 17 years old in Kenya and Ghana, starting in July 2024.